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INTRODUCTION
In June 2013, the Supreme Court of the United States decided the
Association for Molecular Pathology v. Myriad Genetics case.1 That decision
will change the future of patent eligible subject matter. The decision was one
of the first cases the Supreme Court determined after the adoption of the
America Invents Act of 2013 (“AIA”).2 Specifically, the Myriad decision deals
with 35 U.S.C. §101 and patent eligible subject matter related to gene patents.3
The circuit court initially held that both isolated DNA and synthetically created
complimentary DNA (cDNA) were patent eligible subject matter under section

1.
2.
3.

Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107 (2013).
Leahy-Smith America Invents Act, H.R. 1249, 112th Cong. (2011-12).
Myriad Genetics, Inc., 133 S. Ct. 2107.
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101 of the AIA.4 The Supreme Court reversed in part finding that isolated
DNA, comprised of naturally occurring segments of DNA, is not patent eligible
subject matter.5 However, the Supreme Court found that synthetically created
cDNA was not naturally occurring because cDNA has been stripped of its noncoding intron component and contains only the coding exon portion of the
DNA.6 Therefore, cDNA does not occur in nature and falls within the scope of
patent eligible subject matter.7 There have been several district court cases8
and two circuit court cases9 that have analyzed subject matter eligibility in light
of the Myriad decision.
This Comment is divided into two sections. The first section interprets and
analyzes how district courts and circuit courts determine patentable subject
matter under the guidance of the Myriad decision. The second section of the
Comment approaches the issue from the perspective of a law student with a
background in molecular and cellular biology. The second section attempts to
understand and predict the future of patentable subject matter eligibility in light
of the Myriad Supreme Court decision and its progeny.
I. MYRIAD AND PATENTABLE SUBJECT MATTER
The Myriad decision is the leading authority on gene patents subject matter
eligibility.10 The Court in Myriad addressed the issue of patenting isolated
genes and cDNA sequences.11 Section 101 of the Patent Act12 permits patents
to be issued to “[w]hoever invents or discovers any new and useful . . .
composition of matter,” “but laws of nature, natural phenomena, and abstract
ideas are basic tools of scientific and technological work that lie beyond the
domain of patent protection.”13 The Myriad subject matter analysis relies
heavily on the Supreme Court’s analysis in Mayo Collaborative Services.14

4. Ass’n for Molecular Pathology v. USPTO, 689 F.3d 1303, 1328 (Fed. Cir. 2012).
5. Myriad Genetics, Inc., 133 S. Ct. at 2119.
6. Id.
7. Id.
8. Genetic Techs. Ltd. v. Bristol-Myers Squibb Co., 72 F. Supp. 3d 521, 523 (D. Del. 2014);
Ariosa Diagnostics, Inc, v. Sequenom, Inc., 19 F. Supp. 3d 938, 942 (N.D. Cal. 2013); In re BRCA1and BRCA2- Based Hereditary Cancer Test Patent Litig., 3 F. Supp. 3d 1213 (D. Utah 2014); Genetic
Techs. Ltd. v. Agilent Techs., 24 F. Supp. 3d 922 (N.D. Cal. 2014); Genetic Techs. Ltd. v. Lab. Corp.
of Am. Holdings, No. 12-1736-LPS-CJB, 2014 WL 4379587 (D. Del. Sept. 3, 2014).
9. In re Roslin Inst. (Edinburgh), 750 F.3d 1333 (Fed. Cir. 2014); In re BRCA1- and BRCA2Based Hereditary Cancer Test Patent Litig., 774 F.3d 755 (Fed. Cir. 2014).
10. See generally Myriad Genetics Inc., 133 S. Ct. 2107 (2013).
11. Id.
12. Leahy-Smith America Invents Act, H.R. 1249, 112th Cong. (2011-12).
13. Mayo Collaborative Servs. v. Prometheus Labs. Inc., 566 U.S. 66 (2012).
14. See generally Myriad Genetics Inc., 133 S. Ct. 2107 (2013).
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The holding in Myriad is that isolated genes do not fall within the category
of patentable subject matter because they are naturally occurring.15 However,
the Court made the distinction that cDNA, which is synthetically created in a
laboratory and is not naturally occurring, is patent eligible.16 Since the decision
in June of 2013, several district courts have engaged in an analysis of patent
eligible subject matter.17 Two federal circuit cases use the Myriad decision in
the courts’ holdings.18 In order to understand where the future of gene patents
is going, we must first look to how the cases since the Myriad decision are
interpreted and applied, both at the district and federal level.
A. District Courts’ Interpretation of Patentable Subject Matter
in Light of the Myriad Decision
Several district court decisions have been decided since the outcome of the
Myriad decision in June 2013, which cite to and interpret the analysis
performed by the Supreme Court.19 The Myriad decision relies heavily on the
analysis performed by the Supreme Court in Mayo Collaborative.20 The
question presented by the Supreme Court in Mayo is, “do the patent claims add
enough to their statements of the correlations to allow the processes they
describe to qualify as patent-eligible processes that apply natural laws?”21 The
Court in Myriad took up this analysis in its statement that isolated DNA was
simply DNA that was isolated from a cell, which was naturally occurring and
not patent eligible subject matter, but that cDNA was synthetically created in a
laboratory and not occurring in nature therefore cDNA did fall within
patentable subject matter.22

15. Id.
16. Id.
17. Genetic Techs. Ltd. v. Bristol-Myers Squibb Co., 72 F. Supp. 3d 521, 523 (D. Del. 2014);
Ariosa Diagnostics, Inc., v. Sequenom, Inc., 19 F. Supp. 3d 938, 942 (N.D. Cal. 2013); In re BRCA1and BRCA2- Based Hereditary Cancer Test Patent Litig., 3 F. Supp. 3d 1213 (D. Utah 2014); Genetic
Techs. Ltd. v. Agilent Techs., Inc., 24 F. Supp. 3d 922 (N.D. Cal. 2014); Genetic Techs. Ltd. v. Lab.
Corp. of Am. Holdings, No. 12-1736-LPS-CJB, 2014 WL 4379587 (D. Del. Sept. 3, 2014).
18. In re Roslin Inst. (Edinburgh), 750 F.3d 1333 (Fed. Cir. 2014).; In re BRCA1- and BRCA2Based Hereditary Cancer Test Patent Litig., 774 F.3d 755 (Fed. Cir. 2014).
19. Bristol-Myers Squibb Co., 72 F. Supp. 3d at 523; Ariosa Diagnostics, Inc., 19 F. Supp. 3d
938; In re BRCA1- and BRCA2- Based Hereditary Cancer Test 3 F. Supp. 3d 1213, 1217; Agilent
Techs., Inc., 24 F. Supp. 3d 922; Genetic Techs. Ltd. v. Lab. Corp. of Am. Holdings, No. 12-1736LPS-CJB, 2014 WL 4379587 (D. Del. Sept. 3, 2014).
20. See Myriad Genetics Inc., 133 S. Ct. 2107 (2013).
21. Mayo Collaborative Servs. v. Prometheus Labs., Inc., 566 U.S. 66 (2012).
22. See generally Myriad Genetics Inc., 133 S. Ct. 2107 (2013).
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1. Arisoa Dignostics, Inc. v. Sequenom, Inc. (Northern District of California)
The district court case Arisoa Diagnostics v. Sequenom, Inc. involves
claims that are similar to the isolated DNA claims of the Myriad patent.23 The
court stated that “he who discovers a hitherto unknown phenomenon of nature
has no claim to a monopoly of it . . . [t]his is true even if the discovery . . . [is]
considered groundbreaking, innovative, or brilliant.”24 “A process or method
is not unpatentable simply because it contains a law of nature, a natural
phenomenon, or an abstract idea.”25 It is well settled in case law that “to be
patentable, a process that focuses upon the use of a natural law, a natural
phenomenon, or an abstract idea must contain other elements or a combination
of elements, referred to as an ‘inventive concept.’”26 In Myriad, the Court went
even further in its analysis of what is considered naturally occurring stating that
“[s]imply appending conventional steps, specified at a high level of generality,
to laws of nature, natural phenomena, and abstract ideas cannot make those
laws, phenomena, and ideas patentable.”27 “The [Ariosa] Court’s conclusion
conforms [to] the relevant Supreme Court case law, in particular Flook and
Myriad,” “even though Myriad involved composition claims rather than
method claims.”28
The fact that Myriad involves composition claims and Ariosa involves
method claims does not change the analysis performed by the court.29
“Although the Supreme Court [in Myriad] was not presented with method
claims, the Court explained ‘had Myriad created an innovative method of
manipulating genes while searching for the BRCA1 and BRCA2 genes, it could
possibly have sought a method patent.’”30 Had Myriad sought protection for a
method for DNA isolation of the BRCA1 and BRCA2 genes, the method would
likely still be found to be ineligible subject matter. The method patent for
Myriad’s isolated DNA would be found to be ineligible subject matter because
“the processes used by Myriad to isolate DNA were well understood by
geneticists at the time of Myriad’s patents.”31 Had the inventors in Ariosa
“created an innovative method of performing DNA detection while searching
for paternally inherited cffDNA . . . those claims would be patentable.”32
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.

Ariosa Diagnostics, Inc., 19 F. Supp. 3d 938.
Id. at 948.
Mayo Collaborative Servs., 566 U.S. at 70.
Id. See also Parker v. Flook, 437 U.S. 584 (1978).
Ariosa Diagnostics, Inc., 19 F. Supp. 3d 938.
Id. at 950.
Id.
Id.
Id.
Id.
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However, “the claims presently before the court simply rely on processes to
detect DNA that—as Sequenom (inventor) concedes—were conventional
techniques by those in the field at the time of the invention.”33
From Ariosa, it is clear that the District Court of the Northern District of
California places emphasis on the naturally occurring element of patentable
subject matter.34 Ariosa uses well-known Supreme Court cases in establishing
the background for its understanding of Myriad.35 Additionally, the Ariosa
court does not solely rely on the holding and reasoning of the Myriad decision,
but includes the reasoning from previous Supreme Court decisions in its
determination of what constitutes patent eligible subject matter under section
101.36
2. In re BRCA1-, BRCA2-Based Hereditary Cancer Test Patent Litigation
(District Court of Utah)
The District Court of Utah takes a similar approach to that of the Northern
District of California in its interpretation and application of the Myriad
decision. The District Court of Utah, in In re BRCA1, BRCA2, again uses
previous Supreme Court decisions along with the Myriad analysis and
specifically looks to the Mayo decision to aid in its analysis.37 The language
the court adopts from Mayo is “[p]atents drawn to be processes focused on
patent ineligible subject matter may likewise be patent ineligible, unless the
processes include an ‘inventive concept’ sufficient to ‘ensure that the patent in
practice amount to significantly more than a patent upon the natural law
itself.’”38 The In re BRCA1, BRCA2 court adopts much of the language from
the Myriad decision.39 Regarding the exceptions of section 101 patentable
subject matter, the court says, “patents granted over these basic tools create
‘considerable danger’ and that their use would be ‘tied up,’ thereby ‘inhibit[ing]
future innovations premised upon them.’”40 Following the guidance laid out
in Mayo, “[t]he Supreme Court cautions that these exceptions to section 101
should be applied with care, as ‘all inventions at some level embody, use,
reflect, rest upon or apply laws of nature, natural phenomena, or abstract

33. Id.
34. Id. at 948.
35. See generally Mayo Collaborative Servs. v. Prometheus Labs, Inc., 566 U.S. 66 (2012);
see also Parker v. Flook, 437 U.S. 584 (1978).
36. See generally Ariosa Diagnostics, Inc., 19 F. Supp. 3d 938.
37. In re BRCA1- and BRCA2- Based Hereditary Cancer Test Patent Litig., 3 F. Supp. 3d
1213, 1217 (D. Utah 2014).
38. Id. at 1258.
39. Id.
40. Id.
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ideas.’”41
The inventors in the In re BRCA1, BRCA2 case argued that because their
primer claims are drawn to synthetic DNA, their BRCA1 and BRCA2 primers
are patent eligible.42 The district court rejected that argument because the
inventor’s primer claims are drawn to patent ineligible products of nature.43
Additionally, the inventors in this case argued that because the “Court [in
Myriad] found patent ineligible only isolated . . . genomic, extracted DNA, then
the Court must have in blanket fashion ‘affirmed the patent eligibility of
synthetic DNA,’ finding that ‘unlike isolated human genes, synthetic DNA is
man-made and not a product of nature.’”44 The district court rejects this
argument, specifically stating, “the only synthetic DNA the [Myriad] court
expressly found patent eligible was cDNA, [and] even then, the Court held only
that cDNA may be patent eligible under some circumstances:”
As a result, cDNA is not a ‘product of nature’ and is patent-eligible
under section 101, except insofar as very short series of DNA may have
no intervening introns to remove when creating cDNA. In that situation,
a short strand of cDNA may be indistinguishable from natural DNA.45
The district court makes the inference in their conclusion that “if cDNA—
which is clearly synthetic—is sometimes patent ineligible, then implicit in the
Supreme Court’s decision is not all synthetic DNA is patent eligible.”46 The
Myriad Court focused on the fact that the cDNA’s contiguous sequence was
altered in comparison to the sequence from which it was derived.47 The district
court goes further to explain that “this court’s best reading of [Myriad] is that
the Court concluded cDNA sometimes can be sufficiently different from
naturally occurring matter as to merit patent eligibility.”48 However, noncDNA isolated DNA is patent ineligible insofar as “the location and order of
the nucleotides existed in nature.”49 This district court reads the Supreme
Court’s decision in Myriad to “harmonize” with lower court rulings in Myriad,
that non-cDNA isolated DNA includes primers and probes.50 Finally, the

41.
42.
43.
44.
45.
46.
47.
48.
49.
50.

Id. at 1259.
Id.
Id.
Id. at 1261.
Id. at 1262.
Id.
Id.
Id. at 1263.
Id.
Id.
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district “court interprets [Myriad] to stand for the proposition that even
synthetic, non-cDNA, isolated DNA is patent ineligible where it reflects the
same nucleotide sequence as the genomic DNA.”51
The conclusion reached by the District Court of Utah in the In re BRCA1,
BRCA2 decision is consistent with Myriad. However, the Utah District Court
expanded upon the language and interpretation of the Supreme Court language
used in Myriad. Inferring from the language, using the lower court and
Supreme Court Myriad decisions for guidance, and following the backround of
the Mayo Supreme Court patent case law, the District Court of Utah concluded
that the key language of the phrase “synthetic” in the Myriad case is not
dispositive in showing patent eligibility.52
3. Genetic Technologies Ltd v. Bristol-Myers Squibb Company (District Court
of Delaware)
The District Court of Delaware made its own interpretation of Myriad in
October 2014.53 In that case, the plaintiff, Genetic Technologies Ltd.
(“GTG”),54 made the argument that Myriad “stands for the proposition that
‘man-made DNA that is molecularly different from naturally occurring DNA
is patent eligible in of itself.’”55 The District Court, however, said that the
plaintiffs misread Myriad.56 The plaintiffs contend that amplified DNA is
equivalent to cDNA and should fall within the category of patent eligible
subject matter.57
“GTG concedes that ‘like cDNA, the nucleotide sequence of amplified
DNA is dictated by the naturally occurring DNA.’”58 However, GTG argued
that “the process of amplification does not copy the methylation status of the
DNA and incorporates cytosines into the final product of the naturally
occurring 5-methylcytosines.59 The district court stated that, “[an] attempt to
liken amplified DNA to cDNA contradicts the reasoning of Myriad and related
Federal Circuit precedent, which focuses on what the claims recite rather than
unclaimed chemical differences identified post-hoc during litigation.”60 The
court goes even further to make its point, using language from the Myriad
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.

Id.
Id.
Genetic Techs. Ltd. v. Bristol-Myers Squibb Co., 72 F. Supp. 3d 521, 523 (D. Del. 2014).
Id.
Id. at 536.
Id.
Id.
Id.
Id.
Id.
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decision, stating that the methylation argument brought by GTG does not make
their product patent eligible.61 The Supreme Court language stated, “‘Claims
are simply not expressed in terms of chemical composition, nor do they rely in
any way on the chemical changes that result from the isolation of a particular
section of DNA,’ but rather ‘focus on the genetic information encoded in the
BRCA1 and BRCA2 genes.’”62 The District Court distinguished this from the
Supreme Court holding in Myriad because the “claims on cDNA presented no
such problem because removal of the non-coding region sequence
‘unquestionably creates something new,’ even though the coding regions are
retained.”63 Claim 1 in this case recites a method for detecting a coding region
allele using genomic DNA, which is then amplified.64 “[T]he nucleotide
sequence of amplified DNA is dictated by the naturally occurring DNA.” 65
“Therefore, although amplification is carried out in a laboratory by a human, it
is a replication of the native DNA sequence, resulting in a mirror image of the
naturally-occurring genetic information.”66
The District Court of Delaware chose to focus on the functionality of the
product as compared to the actual product itself. The methylation step while
technically creating a “new” coding sequence does not alter the functionality of
the coding process itself. Essentially, the court explained that all GTG did was
add this methyl group marker; this addition did not change the overall structure
or function of the sequence in question. Because the only change was a
minimal methylation, the court did not view this as enough of an inventive step
to cause the sequence to fall into the category of patent eligible subject matter.
4. Genetic Technologies Limited v. Agilent Technologies (Northern District
of California)
The technology involved in this case includes a method claim “for
analyzing variations in non-coding intron sequences to detect linked coding
region alleles and haplotypes.”67 Specifically, the claimed methods involve
“amplifying genomic DNA with a primer pair that spans a non-coding region
sequence” and use this primer pair to detect alleles.68 Additionally, this case
focused on whether the defendant’s motion to dismiss will survive the clear and

61.
62.
63.
64.
65.
66.
67.
68.

Id.
Id.
Id.
Id.
Id.
Id.
Genetic Techs. Ltd. v. Agilent Techs., Inc., 24 F. Supp. 3d 922, 926 (N.D. Cal. 2014).
Id.
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convincing standard.69 The court ultimately denied the defendant’s motion to
dismiss on the grounds that Agilent did not show by clear and convincing
evidence that the patent claims are not meaningfully limited applications of
natural laws.70
The court in Agilent only used the Myriad analysis twice.71 The way in
which the court used the Myriad decision was to establish background on what
the Supreme Court had said about DNA.72 This analysis does not shed much
light on how the court applied the Myriad decision to the present case; instead
it merely served to identify what introns are in the context of DNA.73 The
second mention of the Myriad case is more applicable to this paper as it relates
to how the court interpreted footnote seventeen of the case.74 Footnote
seventeen states that “Agilent argues that, unlike cDNA, amplified DNA is not
patent eligible under Myriad. Even so, GTG does not purport to have patented
the amplified DNA itself, but rather methods utilizing amplified DNA.”75 The
Court in Myriad was careful to point out that its decision did not reach any
method claims or applications of natural laws.”76
The court, in denying the motion to dismiss, is going towards a finding that
this case may involve subject matter that cannot be patented. More and more,
courts are looking into naturally occurring elements of patents. In this case
specifically, the court did not find clear and convincing evidence that the
subject matter itself was not, generally speaking, naturally occurring.
B. Federal Circuits’ Application of the Myriad Interpretation
The Federal Circuit has heard two cases arising out of the litigation
following the Myriad decision.77 Both of these cases will serve to help
understand where the future of gene patents lies. Because patents cases are
federally regulated, the Federal Circuit cases yield more insight as to how lower
courts are ultimately interpreting and applying the Myriad decision. The first
case heard in the Federal Circuit was In re Roslin Institute, decided May 8,

69. Id. at 927.
70. Id. at 923.
71. Id. at 926.
72. Id.
73. Id.
74. Id. at 933, n. 17.
75. Id.
76. Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107, 2119–2120
(2013).
77. In re Roslin Inst. (Edinburgh), 750 F.3d 1333 (Fed. Cir. 2014); In re BRCA1- and BRCA2Based Hereditary Cancer Test Patent Litig., 774 F.3d 755 (2014).
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2014.78 Roslin was subsequently followed by In re BRCA1, BRCA2, which was
decided December 17, 2014.
1. In re Roslin Institute
This case is about the first large mammal cloned from an adult somatic cell:
Dolly the sheep.79 A clone is defined in this case as “an identical genetic copy
of a cell, cell part, or organism.”80 In order to achieve this scientific
breakthrough, the scientists performed a technique known as somatic cell
nuclear transfer.81 The patent at issue in this case, however, is not the somatic
cell nuclear transfer technique.82 Inventors attempted to gain a patent on the
actual clones themselves, which was rejected by an examiner at the United
States Patent and Trademark Office.83 The examiners rejected the claims
because they were directed at non-statutory subject matter under section 101,
and the examiners’ rejections were upheld by the Board of Examiners.84 The
Federal Circuit here undertook a de novo analysis of the Board’s rejection of
patent eligibility.85
The first analysis of the Federal Circuit points out that even before the
Myriad decision, the Supreme Court’s opinions in Chakrabarty and Funk Bros,
“made clear that that naturally occurring organisms are not patentable.”86
Roslin makes the argument that “copies (clones) are eligible for protection
because they are ‘the product of human ingenuity’ and ‘not nature’s handiwork,
but [their] own.’”87 The Federal Circuit compares the clones made by Roslin
to the isolated DNA in the Myriad case.88 The Federal Circuit specifically
stated that Roslin “‘did not create or alter any of the genetic information’ of its
claimed clones, ‘[n]or did [Roslin] create or alter the genetic structure of [the]
DNA’ used to make its clones.”89
The Federal Circuit affirmed the Board’s finding that Roslin’s clones were
unpatentable subject matter for several different reasons.90 The key underlying
theme to the affirmation of the rejection was the fact that the clones are
78.
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
89.
90.

In re Roslin Inst., 750 F.3d 1333.
Id. at 1334.
Id. at 1337.
Id.
Id.
Id. at 1338.
Id.
Id.
Id. at 1336.
Id. at 1337.
Id.
Id.
Id.
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naturally occurring.91 The Federal Circuit stated, “the claims do not describe
clones that have markedly different characteristics from the donor animals of
which they are copies.”92 From this language, it is clear that the Federal Circuit
is looking at the differences between the clones and the naturally-occurring
sheep, concluding that there were no differences between them, and thus the
clones did not fall within the category of patentable subject matter.
2. In re BRCA1, BRCA2
This case arises out of the initial Myriad Supreme Court decision.93 It
involves patents that were not considered in the Myriad decision.94 At issue in
this specific litigation are two types of claims, (1) composition of matter claims,
and (2) method claims.95 The composition of matter claims involve two DNA
primers, which are “short, synthetic, single-stranded DNA molecule[s] that
bind . . . specifically to . . . intended target nucleotide sequence[s].”96 The
method claims at issue involve comparisons between wild-type BRCA
sequences and the patient’s BRCA sequences.97 The Federal Circuit looks first
to the composition of matter claims and then to the method claims.98
The Supreme Court decision in Myriad guides the Federal Circuit in its
analysis of the primer claims under section 101.99 The Federal Circuit, in its
analysis of the primer claims, articulates that primers “are not distinguishable
from the isolated DNA found patent-ineligible in Myriad and are not similar to
the patent-eligible cDNA.”100 The Court goes further to explain that because
the primers “contain the identical sequence of the BRCA sequence directly
opposite to the strand they are designed to bind . . . they are structurally
identical to the ends of DNA strands found in nature.”101 Additionally, the
Court states “it makes no difference” that the primers are “synthetically
replicated.”102 The Court again looks to the functionality when determining
whether the primers are different from their naturally occurring counterparts.103
91. Id. at 1339.
92. Id.
93. In re BRCA1- and BRCA2- Based Hereditary Cancer Test Patent Litig., 774 F.3d 755, 758
(Fed. Cir. 2014).
94. Id.
95. See generally id.
96. Id.
97. Id.
98. Id. at 759.
99. Id.
100. Id. at 760.
101. Id.
102. Id.
103. Id. at 760–61.
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The Federal Circuit explains “the naturally occurring sequences at issue here
do not perform a significantly new function.”104 The Federal Court, in regards
to functionality, reads the Supreme Court’s decision in Myriad to mean “A
DNA structure with a function similar to that found in nature can only be patent
eligible as a composition of matter if it has a unique structure, different from
anything found in nature.”105
II. CONCLUSION
Based on the District Court’s and Federal Circuit’s interpretation of Myriad
regarding patentable subject matter it is reasonable to conclude that the court
now looks to functionality in determining whether or not something is naturally
occurring. In the District Court cases, this was illustrated when the court
rejected the argument that a mere methylation created something new. The
argument that the methylation added a methyl group essentially creating a
“new” molecule did not hold weight because, in the court’s mind, the
functionality was still the same. This move towards functionality being a part
of the naturally occurring analysis is also starting to occur in the Federal Circuit.
When looking at the In re Roslin and In re BRCA1 cases, it is clear that courts
are looking on a broader scale to determine whether the thing in question is
naturally occurring. This will be important an important factor going forward
in gene patentability.
The courts are essentially making the test of whether a matter is naturally
occurring more difficult to overcome, in the sense that just because of the fact
that the matter is made in a lab does not automatically preclude it from being
considered naturally occurring. Quite the opposite, actually. The standard for
showing something is not naturally occurring is becoming difficult to meet,
especially now that courts are not looking just to the structure of the molecule
or gene, but also the functionality. This can possibly be a dangerous road to
travel down, because functionality is a very important part of patents. It is my
opinion that adding a methyl group to a molecule, while maybe not changing
the function of the molecule, substantially changes the molecule. This change,
while not naturally occurring, is now seen by courts as not being enough to
provide the molecule patent protection. I think that this is an erroneous
interpretation and has the potential to cause devastating outcomes in the future
regarding the patenting of genes and genetic products.
In conclusion, I caution the courts when applying this functionality test in
making the determination of when something is naturally occurring.
Functionality now plays an important part in the patent system, and creating a
104. Id.
105. Id. at 761.
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more difficult hurdle in the gene patent sector could lead to stagnant innovation
in a field that cannot afford to be stagnant.
NATHAN EDWARD CROMER*

*

J.D., Marquette University Law School, May 2015.

